Table 2.

Phase 3 trials evaluating novel agent-based consolidation therapy after ASCT

Phase 3 trials evaluating novel agent-based consolidation therapy after ASCT

BORT indicates bortezomib.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal